Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A (600613) - Net Assets
Based on the latest financial reports, Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A (600613) has net assets worth CN¥2.41 Billion CNY (≈ $352.57 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.09 Billion ≈ $451.61 Million USD) and total liabilities (CN¥676.78 Million ≈ $99.03 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 600613 financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.41 Billion |
| % of Total Assets | 78.07% |
| Annual Growth Rate | 6.97% |
| 5-Year Change | 4.26% |
| 10-Year Change | 6.17% |
| Growth Volatility | 122.09 |
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A - Net Assets Trend (1992–2024)
This chart illustrates how Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A's net assets have evolved over time, based on quarterly financial data. Also explore Shanghai Shenqi Pharmaceutical Investmen asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A (1992–2024)
The table below shows the annual net assets of Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A from 1992 to 2024. For live valuation and market cap data, see Shanghai Shenqi Pharmaceutical Investmen market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.43 Billion ≈ $355.12 Million |
+1.52% |
| 2023-12-31 | CN¥2.39 Billion ≈ $349.81 Million |
+0.73% |
| 2022-12-31 | CN¥2.37 Billion ≈ $347.27 Million |
-0.81% |
| 2021-12-31 | CN¥2.39 Billion ≈ $350.10 Million |
+2.78% |
| 2020-12-31 | CN¥2.33 Billion ≈ $340.61 Million |
-12.54% |
| 2019-12-31 | CN¥2.66 Billion ≈ $389.47 Million |
+2.42% |
| 2018-12-31 | CN¥2.60 Billion ≈ $380.28 Million |
+2.70% |
| 2017-12-31 | CN¥2.53 Billion ≈ $370.30 Million |
+3.93% |
| 2016-12-31 | CN¥2.43 Billion ≈ $356.31 Million |
+6.52% |
| 2015-12-31 | CN¥2.29 Billion ≈ $334.49 Million |
+14.41% |
| 2014-12-31 | CN¥2.00 Billion ≈ $292.37 Million |
+10.26% |
| 2013-12-31 | CN¥1.81 Billion ≈ $265.15 Million |
+699.61% |
| 2012-12-31 | CN¥226.61 Million ≈ $33.16 Million |
+7.15% |
| 2011-12-31 | CN¥211.50 Million ≈ $30.95 Million |
+9.94% |
| 2010-12-31 | CN¥192.37 Million ≈ $28.15 Million |
+4.87% |
| 2009-12-31 | CN¥183.43 Million ≈ $26.84 Million |
-12.16% |
| 2008-12-31 | CN¥208.82 Million ≈ $30.56 Million |
+2.22% |
| 2007-12-31 | CN¥204.29 Million ≈ $29.89 Million |
+8.38% |
| 2006-12-31 | CN¥188.49 Million ≈ $27.58 Million |
+1.93% |
| 2005-12-31 | CN¥184.92 Million ≈ $27.06 Million |
+4.94% |
| 2004-12-31 | CN¥176.21 Million ≈ $25.79 Million |
+17.29% |
| 2003-12-31 | CN¥150.23 Million ≈ $21.98 Million |
+2.80% |
| 2002-12-31 | CN¥146.14 Million ≈ $21.38 Million |
-41.97% |
| 2001-12-31 | CN¥251.84 Million ≈ $36.85 Million |
-30.27% |
| 2000-12-31 | CN¥361.16 Million ≈ $52.85 Million |
+7.25% |
| 1999-12-31 | CN¥336.74 Million ≈ $49.28 Million |
-7.30% |
| 1998-12-31 | CN¥363.26 Million ≈ $53.16 Million |
-0.08% |
| 1997-12-31 | CN¥363.54 Million ≈ $53.20 Million |
+3.90% |
| 1996-12-31 | CN¥349.90 Million ≈ $51.20 Million |
+9.46% |
| 1995-12-31 | CN¥319.66 Million ≈ $46.78 Million |
-2.41% |
| 1994-12-31 | CN¥327.54 Million ≈ $47.93 Million |
+3.55% |
| 1993-12-31 | CN¥316.31 Million ≈ $46.29 Million |
+12.64% |
| 1992-12-31 | CN¥280.81 Million ≈ $41.09 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3473.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥752.17 Million | 31.83% |
| Common Stock | CN¥534.07 Million | 22.60% |
| Other Comprehensive Income | CN¥252.05 Million | 10.67% |
| Other Components | CN¥824.74 Million | 34.90% |
| Total Equity | CN¥2.36 Billion | 100.00% |
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A Competitors by Market Cap
The table below lists competitors of Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shanghai W Ibeda High Tech Group Co Ltd
SHG:688071
|
$412.42 Million |
|
Fubotv Inc
NYSE:FUBO
|
$412.68 Million |
|
Tegma Gestão Logística S.A
SA:TGMA3
|
$412.73 Million |
|
Community Health Systems Inc
NYSE:CYH
|
$412.79 Million |
|
BlackRock Energy and Resources Closed Fund
NYSE:BGR
|
$412.39 Million |
|
Cion Investment Corp
NYSE:CION
|
$412.33 Million |
|
Hanjia Design Croup Co Ltd Class A
SHE:300746
|
$412.25 Million |
|
HiVi Acoustics Technology Co Ltd
SHE:002888
|
$412.22 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,335,387,196 to 2,363,038,500, a change of 27,651,304 (1.2%).
- Net income of 71,388,047 contributed positively to equity growth.
- Dividend payments of 64,182,304 reduced retained earnings.
- Other comprehensive income increased equity by 14,395,975.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥71.39 Million | +3.02% |
| Dividends Paid | CN¥64.18 Million | -2.72% |
| Other Comprehensive Income | CN¥14.40 Million | +0.61% |
| Other Changes | CN¥6.05 Million | +0.26% |
| Total Change | CN¥- | 1.18% |
Book Value vs Market Value Analysis
This analysis compares Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.37x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.73x to 1.37x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1992-12-31 | CN¥1.57 | CN¥5.88 | x |
| 1993-12-31 | CN¥1.75 | CN¥5.88 | x |
| 1994-12-31 | CN¥1.81 | CN¥5.88 | x |
| 1995-12-31 | CN¥1.76 | CN¥5.88 | x |
| 1996-12-31 | CN¥1.93 | CN¥5.88 | x |
| 1997-12-31 | CN¥2.01 | CN¥5.88 | x |
| 1998-12-31 | CN¥1.81 | CN¥5.88 | x |
| 1999-12-31 | CN¥1.82 | CN¥5.88 | x |
| 2000-12-31 | CN¥1.85 | CN¥5.88 | x |
| 2001-12-31 | CN¥1.36 | CN¥5.88 | x |
| 2002-12-31 | CN¥0.76 | CN¥5.88 | x |
| 2003-12-31 | CN¥0.78 | CN¥5.88 | x |
| 2004-12-31 | CN¥0.89 | CN¥5.88 | x |
| 2005-12-31 | CN¥0.94 | CN¥5.88 | x |
| 2006-12-31 | CN¥0.95 | CN¥5.88 | x |
| 2007-12-31 | CN¥1.04 | CN¥5.88 | x |
| 2008-12-31 | CN¥1.08 | CN¥5.88 | x |
| 2009-12-31 | CN¥0.93 | CN¥5.88 | x |
| 2010-12-31 | CN¥1.02 | CN¥5.88 | x |
| 2011-12-31 | CN¥1.09 | CN¥5.88 | x |
| 2012-12-31 | CN¥0.56 | CN¥5.88 | x |
| 2013-12-31 | CN¥3.87 | CN¥5.88 | x |
| 2014-12-31 | CN¥4.36 | CN¥5.88 | x |
| 2015-12-31 | CN¥4.53 | CN¥5.88 | x |
| 2016-12-31 | CN¥4.41 | CN¥5.88 | x |
| 2017-12-31 | CN¥4.56 | CN¥5.88 | x |
| 2018-12-31 | CN¥4.79 | CN¥5.88 | x |
| 2019-12-31 | CN¥4.99 | CN¥5.88 | x |
| 2020-12-31 | CN¥4.27 | CN¥5.88 | x |
| 2021-12-31 | CN¥4.38 | CN¥5.88 | x |
| 2022-12-31 | CN¥4.32 | CN¥5.88 | x |
| 2023-12-31 | CN¥4.51 | CN¥5.88 | x |
| 2024-12-31 | CN¥4.30 | CN¥5.88 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.02%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.48%
- • Asset Turnover: 0.66x
- • Equity Multiplier: 1.32x
- Recent ROE (3.02%) is above the historical average (0.12%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1992 | 7.49% | 22.20% | 0.26x | 1.30x | CN¥-7.04 Million |
| 1993 | 11.31% | 19.75% | 0.42x | 1.35x | CN¥4.08 Million |
| 1994 | 9.15% | 13.81% | 0.44x | 1.51x | CN¥-2.74 Million |
| 1995 | 6.99% | 10.36% | 0.43x | 1.56x | CN¥-9.47 Million |
| 1996 | 4.03% | 6.13% | 0.44x | 1.50x | CN¥-20.57 Million |
| 1997 | 2.69% | 3.61% | 0.46x | 1.61x | CN¥-26.15 Million |
| 1998 | 1.21% | 3.37% | 0.15x | 2.32x | CN¥-28.38 Million |
| 1999 | 1.99% | 6.15% | 0.22x | 1.50x | CN¥-25.95 Million |
| 2000 | 2.03% | 12.01% | 0.11x | 1.61x | CN¥-26.26 Million |
| 2001 | -18.04% | -118.79% | 0.09x | 1.69x | CN¥-67.88 Million |
| 2002 | -75.74% | -813.26% | 0.04x | 2.13x | CN¥-116.50 Million |
| 2003 | -20.03% | -115.65% | 0.08x | 2.07x | CN¥-42.03 Million |
| 2004 | 9.47% | 19.82% | 0.21x | 2.27x | CN¥-848.73K |
| 2005 | 4.65% | 11.14% | 0.24x | 1.76x | CN¥-8.94 Million |
| 2006 | 1.70% | 4.64% | 0.21x | 1.73x | CN¥-14.12 Million |
| 2007 | 7.45% | 20.91% | 0.22x | 1.59x | CN¥-4.73 Million |
| 2008 | 2.32% | 6.30% | 0.27x | 1.38x | CN¥-14.54 Million |
| 2009 | -14.32% | -30.81% | 0.32x | 1.47x | CN¥-40.29 Million |
| 2010 | 3.26% | 5.36% | 0.48x | 1.27x | CN¥-11.71 Million |
| 2011 | 9.17% | 11.84% | 0.61x | 1.27x | CN¥-1.58 Million |
| 2012 | 6.68% | 8.90% | 0.61x | 1.22x | CN¥-6.80 Million |
| 2013 | 6.25% | 12.00% | 0.47x | 1.12x | CN¥-67.03 Million |
| 2014 | 9.16% | 13.93% | 0.57x | 1.15x | CN¥-16.42 Million |
| 2015 | 9.72% | 13.61% | 0.60x | 1.20x | CN¥-6.27 Million |
| 2016 | 7.72% | 11.39% | 0.53x | 1.27x | CN¥-53.83 Million |
| 2017 | 5.26% | 7.47% | 0.56x | 1.26x | CN¥-116.74 Million |
| 2018 | 4.18% | 5.73% | 0.59x | 1.23x | CN¥-147.89 Million |
| 2019 | 3.21% | 4.36% | 0.54x | 1.36x | CN¥-177.72 Million |
| 2020 | -15.52% | -19.43% | 0.59x | 1.36x | CN¥-581.21 Million |
| 2021 | 2.97% | 3.02% | 0.73x | 1.34x | CN¥-164.81 Million |
| 2022 | 2.09% | 2.03% | 0.71x | 1.45x | CN¥-184.20 Million |
| 2023 | 2.44% | 2.43% | 0.71x | 1.40x | CN¥-176.54 Million |
| 2024 | 3.02% | 3.48% | 0.66x | 1.32x | CN¥-164.92 Million |
Industry Comparison
This section compares Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $1,737,975,810
- Average return on equity (ROE) among peers: 11.55%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A (600613) | CN¥2.41 Billion | 7.49% | 0.28x | $412.42 Million |
| Zhejiang Int'L Group Co Ltd (000411) | $916.87 Million | 20.43% | 3.01x | $809.52 Million |
| Zhejiang Zhenyuan Share Co Ltd (000705) | $1.31 Billion | 3.45% | 0.54x | $403.85 Million |
| Hunan Jingfeng Pharmaceutical (000908) | $2.86 Billion | 6.53% | 0.83x | $916.62 Million |
| Hubei Guangji Pharmaceutical Co Ltd (000952) | $1.08 Billion | -27.44% | 1.60x | $374.97 Million |
| Yifan Xinfu Pharmaceutical Co Ltd (002019) | $3.90 Billion | 18.07% | 0.79x | $1.99 Billion |
| Guangdong Jiaying Pharmaceutical Co Ltd (002198) | $82.63 Million | 26.76% | 0.45x | $433.71 Million |
| Sichuan Kelun Pharmaceutical Co Ltd (002422) | $691.22 Million | 31.29% | 1.59x | $8.08 Billion |
| Chongqing Lummy Pharmaceutical (300006) | $1.69 Billion | 1.22% | 0.84x | $987.34 Million |
| Zhejiang Jolly Pharmaceutical Co Ltd (300181) | $2.82 Billion | 18.01% | 0.42x | $1.56 Billion |
| Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) | $2.03 Billion | 17.21% | 0.08x | $1.95 Billion |
About Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd., together with its subsidiaries, operates as a pharmaceutical manufacturing holding investment company in China. The company engages in the research and development, and production of anti-tumor, cardiovascular, cerebrovascular, rheumatism bone pain, tonic and sedative, cold and cough, anti-fungal, gynecology, and other treatment fiel… Read more